Literature DB >> 11372771

Diagnosis and management of acute obstetrical DIC.

T Kobayashi1, T Terao, M Maki, T Ikenoue.   

Abstract

UNLABELLED: Obstetrical disseminated intravascular coagulation (DIC) is usually a very acute, serious complication of pregnancy. The DIC diagnostic criteria in obstetrics (the obstetrical DIC score) help with making a prompt diagnosis and starting treatment early. These DIC diagnostic criteria, in which higher scores are given for clinical parameters than for laboratory parameters, have three components: (1) the underlying disease, (2) clinical symptoms, and (3) laboratory findings. It is justified that it is appropriate to initiate therapy for DIC when the obstetrical DIC score reaches 8 points or more before obtaining the results of coagulation tests. MANAGEMENT: (1) Control of the underlying disease: because prolongation of exposure to the triggering factors worsens DIC, it is important to eliminate the etiologic factors as rapidly as possible. Elimination of the cause of DIC can be easily performed in obstetrics, for example, by cesarean section. (2) Antithrombin (AT) therapy: AT monotherapy (1,500 to 3,000 units/day, 2 days) is preferably employed instead of heparin monotherapy or heparin-AT therapy because of the hemorrhagic side effects of heparin. (3) Synthetic serine protease inhibitors: continuous infusion ofgabexate mesilate (FOY) or nafamostat mesilate (FUT) is effective for DIC. Controlled multicenter trials showed a significant improvement not only in clinical response but also in platelet counts and prothrombin time (PT) in the AT group compared with the FOY group. (4) Activated protein C (APC) can inhibit thrombin generation and accelerate fibrinolytic activity. APC (5,000 to 10,000 units) is administered for 2 days in patients with placental abruption complicated by DIC. APC is a very safe, effective, and useful agent for the treatment of DIC.

Entities:  

Mesh:

Year:  2001        PMID: 11372771     DOI: 10.1055/s-2001-14076

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  14 in total

Review 1.  Transfusion and coagulation management in major obstetric hemorrhage.

Authors:  Alexander J Butwick; Lawrence T Goodnough
Journal:  Curr Opin Anaesthesiol       Date:  2015-06       Impact factor: 2.706

2.  Effect of hypofibrinogenemia on obstetrical disseminated intravascular coagulation in Japan in 2018: a multicenter retrospective cohort study.

Authors:  Mamoru Morikawa; Shigetaka Matsunaga; Shintaro Makino; Yoshiharu Takeda; Hironobu Hyoudo; Masafumi Nii; Mariko Serizawa; Atsuo Itakura; Tomoko Adachi; Takao Kobayashi
Journal:  Int J Hematol       Date:  2021-03-12       Impact factor: 2.490

Review 3.  Danaparoid: a review of its use in thromboembolic and coagulation disorders.

Authors:  Tim Ibbotson; Caroline M Perry
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  The complement inhibitor FUT-175 suppresses T cell autoreactivity in experimental autoimmune encephalomyelitis.

Authors:  Qing Li; Kristine Nacion; Hong Bu; Feng Lin
Journal:  Am J Pathol       Date:  2009-07-16       Impact factor: 4.307

5.  Postpartum haemorrhage from ruptured pseudoaneurysm: efficacy of transcatheter arterial embolisation using N-butyl-2-cyanoacrylate.

Authors:  Gyoung Min Kim; Chang Jin Yoon; Nak Jong Seong; Sung-Gwon Kang; Young-Joo Kim
Journal:  Eur Radiol       Date:  2013-04-05       Impact factor: 5.315

Review 6.  [Hemorrhaging during pregnancy].

Authors:  S Hofer; R Schreckenberger; B Heindl; K Görlinger; H Lier; H Maul; E Martin; M A Weigand
Journal:  Anaesthesist       Date:  2007-10       Impact factor: 1.041

Review 7.  New insights of an old defense system: structure, function, and clinical relevance of the complement system.

Authors:  Christian Ehrnthaller; Anita Ignatius; Florian Gebhard; Markus Huber-Lang
Journal:  Mol Med       Date:  2010-10-29       Impact factor: 6.354

8.  Therapeutic and pharmaco-biological, dose-ranging multicentre trial to determine the optimal dose of TRAnexamic acid to reduce blood loss in haemorrhagic CESarean delivery (TRACES): study protocol for a randomised, double-blind, placebo-controlled trial.

Authors:  Anne-Sophie Bouthors; Benjamin Hennart; Emmanuelle Jeanpierre; Anne-Sophie Baptiste; Imen Saidi; Elodie Simon; Damien Lannoy; Alain Duhamel; Delphine Allorge; Sophie Susen
Journal:  Trials       Date:  2018-03-01       Impact factor: 2.279

9.  Rupture of hidden abnormal myometrial vessels during cesarean delivery of a patient with subserosal leiomyoma: A possible pathogenesis of sudden-onset disseminated intravascular coagulation.

Authors:  Junko Ushijima; Liangcheng Wang; Hiroyoshi Ko; Isao Horiuchi; Kenro Chikazawa; Shigetane Sasaki; Tomoyuki Kuwata; Kenjiro Takagi; Akira Tanaka
Journal:  Clin Case Rep       Date:  2018-07-13

10.  Nafamostat Mesilate Enhances the Radiosensitivity and Reduces the Radiation-Induced Invasive Ability of Colorectal Cancer Cells.

Authors:  Hiroshi Sugano; Yoshihiro Shirai; Takashi Horiuchi; Nobuhiro Saito; Yohta Shimada; Ken Eto; Tadashi Uwagawa; Toya Ohashi; Katsuhiko Yanaga
Journal:  Cancers (Basel)       Date:  2018-10-17       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.